Effect of Drospirenone-Ethinyl Estradiol (20microgram vs 30 Microgram) on Free Androgen Index in PCOS

About this trial

Last updated 5 months ago

Study ID

5162

Status

Completed

Type

Interventional

Phase

N/A

Placebo

Accepting

18 to 35 Years

Female

Trial Timing

Ended a year ago

What is this trial about?

Combined hormonal contraceptive (CHC) improves androgen parameter in women with PCOS. High-dose CHC increases insulin resistance, whereas low dose CHC has minimal effects on carbohydrate metabolism. This quasi experimental study was conducted to compare the effects of Drospirenone-Ethinyl Estradiol (20µg) to that with Drospirenone-Ethinyl Estradiol (30µg) on free androgen index (FAI) in polycystic ovary syndrome. Medication was given for 3 months. FAI, HOMA-IR was measured in baseline and after treatment and results were compared.

What are the Participation Requirements?

Inclusion Criteria: •Age:20-35 years * Diagnosed case of PCOS patients according to Rotterdam criteria * women with PCOS Exclusion Criteria: * Contraindication of OCP such as history of thromboembolic disorder, cerebrovascular disease, coronary artery disease, carcinoma of breast or other estrogen dependent neoplasm, undiagnosed abnormal genital bleeding, known or suspected pregnancy, benign or malignant liver neoplasm, cholestatic jaundice on previous pregnancy, abnormal liver and renal function, uncontrolled DM and HTN, dyslipidemia, history of migraine with focal aura * Recent use of androgen and antiandrogens within 3months * BMI>30kg/m2 * Cause of oligovulation other than PCOS